Rate of motor progression in Parkinson’s disease: a systematic review and meta-analysis DOI Creative Commons

Ayla Pauwels,

Albert L G Phan,

Catherine Ding

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 26, 2024

Background The search for neuroprotective treatments Parkinson’s disease (PD) still relies largely on motor disability scales. A limitation of these tools is the strong influence symptomatic dopaminergic treatment effects. Drawing a wealth published information, we conducted systematic review and meta-analysis progression in PD its relationships with therapy. Methods We searched Medline, Embase, Central to identify 84 publications adequate serial scores calculate progression, expressed as an increase percentage maximum disability. Results random-effects model showed at 2.0% p.a. (95% CI 1.7–2.4%). There were no significant differences by baseline age, sample size, or observation period. However, untreated patients, 8 publications, progressed 4.5% compared 1.6% 76 studies containing individuals drugs ( p = 0.0004, q 0.003). This was supported research phenoconversion prodromal PD, where exceeded 5% 2 years before diagnosis. Starting levodopa improved pre-treatment 40.3 ± 15.2%. Practically defined off state measurements faster than modest degree 0.05). Conclusion survey suggests that accurate long-term assess disease-modifying therapies can be despite sequential commencement attrition over time. While study designs involving avoid confounding effects treatment, different assumptions about may needed. test dose method maximizes information medication cycle once therapy has begun.

Language: Английский

Brain-first vs. body-first Parkinson's disease: An update on recent evidence DOI Creative Commons
Jacob Horsager, Per Borghammer

Parkinsonism & Related Disorders, Journal Year: 2024, Volume and Issue: 122, P. 106101 - 106101

Published: March 15, 2024

We recently proposed a new disease model of Parkinson's – the -Synuclein Origin site and Connectome model. The posits that initial pathology starts either in olfactory bulb or amygdala leading to brain-first subtype, enteric nervous system body-first subtype. These subtypes should be distinguishable early course on range imaging, clinical, neuropathological markers. Here, we review recent original human studies, which tested predictions model.Molecular imaging studies were generally agreement with model, whereas structural such as MRI volumetry, showed conflicting findings. Most large-scale clinical supportive, reporting clustering relevant markers including REM-sleep behavior disorder, constipation, autonomic dysfunction, neuropsychiatric symptoms, cognitive impairment. Finally, -synuclein deposition antemortem postmortem tissues revealed distribution pathology, supports

Language: Английский

Citations

34
Divergent amygdala function in proposed brain-first and body-first Parkinson's disease: a resting-state functional magnetic resonance imaging study DOI

Kunpeng Qin,

Yaqing Li,

Yumei Liu

et al.

Journal of Affective Disorders, Journal Year: 2025, Volume and Issue: 382, P. 123 - 130

Published: April 17, 2025

Language: Английский

Citations

0
Urodynamic study and its correlation with cardiac meta‐iodobenzylguanidine (MIBG) in body‐first and brain‐first subtypes of Parkinson's disease DOI Creative Commons
Min Seung Kim, Jong Keun Kim,

In Hee Kwak

et al.

European Journal of Neurology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Abstract Background and purpose Lower urinary tract symptoms (LUTS) are frequently observed in patients with Parkinson's disease (PD), but the underlying mechanism remains elusive. The concept of “body‐first” “brain‐first” subtypes PD has been proposed, correlation subtype LUTS unclear. We aimed to investigate disparities urological dysfunctions between body‐first brain‐first using urodynamic studies (UDS). Methods reviewed (disease duration <3 years) who had undergone UDS completed questionnaires (Overactive Bladder Symptom Score [OABSS] International Prostate [IPSS]) a voiding diary. Patients were categorized as having or based on cardiac sympathetic denervation (CSD) meta‐iodobenzylguanidine ( MIBG) uptake presence rapid eye movement sleep behavior disorder (RBD), assessed questionnaire (PD CSD RBD indicating subtype). Results A total 55 into n = 37) 18) groups. group exhibited smaller volume first desire (FDV) than p < 0.05 both). Also, higher OABSS IPSS scores, prevalence overactive bladder diagnosed by OABSS, compared group. In multiple linear regression, MIBG was positively correlated FDV negatively all). Conclusions more pronounced impaired storage function early stage disease. Additionally, significantly associated dysfunction.

Language: Английский

Citations

1
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease DOI Open Access
Matteo Conti, Valentina D’Onofrio,

Roberta Bovenzi

et al.

Movement Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Abstract Background Rapid eye movement (REM) sleep behavior disorder (RBD) may precede motor symptoms in Parkinson's disease (PD) by years. According to a recent hypothesis, premotor RBD (pRBD) is marker of the PD body‐first subtype, where synucleinopathy originates from peripheral autonomic nervous system. Conversely, brain‐first pathology would arise brain. Functional connectivity (FC) could provide additional insight into neurodegenerative process these putative subtypes. Objectives We aim analyze possible FC differences between early‐stage patients with (PD pRBD+ ) and without pRBD− pRBD using high‐density electroencephalography (EEG). Methods enrolled 28 , 35 healthy controls (HC). Data were recorded 64‐channel EEG system, source‐reconstruction method was used identify brain‐region activity. calculated weighted phase‐lag index θ, α, β, low‐γ bands. Statistical analysis conducted network‐based statistic. Results found significant trend decreased α‐FC across HC, mainly prefrontal temporal areas. The altered correlated Montreal Cognitive Assessment scores and, lesser extent, gait/postural disturbances only. had similarly increased than HC β band network, predominantly involving sensorimotor limbic network related bradykinesia severity both subgroups. Conclusions Compared (brain‐first subtype), group (body‐first subtype) demonstrates specific EEG‐FC dysfunctions α band, which reflect early involvement cholinergic ascending © 2024 International Parkinson Movement Disorder Society.

Language: Английский

Citations

1
Correlation of olfactory function factors with cardiac sympathetic denervation in Parkinson’s disease DOI
Dong-Woo Ryu, Sang‐Won Yoo, K H Choi

et al.

Journal of Neurology, Journal Year: 2023, Volume and Issue: 271(3), P. 1397 - 1407

Published: Nov. 9, 2023

Language: Английский

Citations

3
Rate of motor progression in Parkinson’s disease: a systematic review and meta-analysis DOI Creative Commons

Ayla Pauwels,

Albert L G Phan,

Catherine Ding

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 26, 2024

Background The search for neuroprotective treatments Parkinson’s disease (PD) still relies largely on motor disability scales. A limitation of these tools is the strong influence symptomatic dopaminergic treatment effects. Drawing a wealth published information, we conducted systematic review and meta-analysis progression in PD its relationships with therapy. Methods We searched Medline, Embase, Central to identify 84 publications adequate serial scores calculate progression, expressed as an increase percentage maximum disability. Results random-effects model showed at 2.0% p.a. (95% CI 1.7–2.4%). There were no significant differences by baseline age, sample size, or observation period. However, untreated patients, 8 publications, progressed 4.5% compared 1.6% 76 studies containing individuals drugs ( p = 0.0004, q 0.003). This was supported research phenoconversion prodromal PD, where exceeded 5% 2 years before diagnosis. Starting levodopa improved pre-treatment 40.3 ± 15.2%. Practically defined off state measurements faster than modest degree 0.05). Conclusion survey suggests that accurate long-term assess disease-modifying therapies can be despite sequential commencement attrition over time. While study designs involving avoid confounding effects treatment, different assumptions about may needed. test dose method maximizes information medication cycle once therapy has begun.

Language: Английский

Citations

0